Cassava Sciences
Cassava Sciences, Inc. is a clinical-stage biotechnology company focused on developing novel treatments for neurodegenerative diseases, primarily Alzheimer's disease. The company's lead investigational drug candidate is simufilam, a small molecule designed to restore the normal shape and function of altered filamin A protein in the brain, which they believe is a key mechanism underlying Alzheimer's pathology.
About Us
- Cassava Sciences is dedicated to the discovery and development of innovative therapies for conditions affecting the brain. - Their core focus is on advancing simufilam through clinical trials for Alzheimer's disease. - They operate with a scientific approach aimed at addressing the molecular basis of neurodegeneration, seeking to provide a new therapeutic option for patients. - The company has faced significant public and scientific scrutiny regarding its research findings and methodologies but continues to pursue clinical development of simufilam.
Vision
To become a leader in neuroscience by providing innovative and effective therapeutic solutions for devastating neurological disorders, specifically aiming to offer a new treatment option for Alzheimer's disease.
Mission
To discover and develop novel treatments for neurodegenerative diseases, with a primary focus on bringing simufilam to patients suffering from Alzheimer's disease.
Specialties & Industries
Open Positions
No open positions at the moment
Check back later for new opportunities